About US
Contact us
-
States say Alvogen lawsuit is part of a 'guerilla' war against the death penaltyIn a battle over lethal execution drugs manufactured by pharma companies, 15 states have backed Nevada in a case alleging drugmaker Alvogen filed a meritless lawsuit only to delay an execution proce2018/8/13
-
China targets Cosentyx, Shingrix and Luxturna and 45 other drugs for priority approvalHey, Big Pharma stars: China wants you. Aiming to speed new drugs to market, China just came up with a target list of 48 treatments greenlighted abroad, including some of the industry's biggest names.2018/8/10
-
Johnson & Johnson CEO Alex Gorsky dines with Trump as president promises ‘substantial’ drug price cutsJohnson & Johnson CEO Alex Gorskyjoined other CEOs fordinner with President Donald Trump and it came with a prelude where Trump told reporters the administration has a planto bringdrug pricesdow2018/8/9
-
Ironwood dumps AstraZeneca gout drug Zurampic—and lays off 125 in the processZurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound up on the scrap heap. On Monday, Ironwood Pharmaceuticals said it would end its Zurampic (lesinurad) lic2018/8/7
-
With IPO filing, Lilly pulls back the curtain on animal health business Elanco—warts and allThat was fast. Little more than a week after investors applauded Eli Lilly's plan to spin off its animal health unit, Elanco, the company has delivered. Itfiled a registration statement with the SE2018/8/6
-
Teva's Copaxone holds its own in wake of Mylan's generic price cutMylan may have toppled list prices on its generic Copaxone, but Teva isn’t worried. After far surpassing quarterly expectationsfor the multiple sclerosis blockbuster in the second quarter, the Israe2018/8/3
-
Pfizer CEO psychs up investors for a rebate-free world under TrumpWhat would a world with no drug rebates look like? Pfizer’s Ian Read is already imagining it. “I would believe we're going to go to a marketplace where we don't have rebates,” he said Tuesday on Pf2018/8/2
-
Thanks to Genzyme—and no thanks to vaccines or diabetes—Sanofi is treading waterAs much as Sanofi has struggled with diabetes and generic drugs the past few years, it could typically count on vaccines and Genzyme to come to the rescue. This quarter, Genzyme played its usual lif2018/8/1
-
Indivior's new antipsychotic wins FDA nod, but Suboxone patent fight could delay its launchJust as Indivior stalledDr. Reddy’s rollout of a generic to its top-selling drug, Suboxone Film, the launch of a new drug of Indivior’s own might become collateral damage of the patent fight and the2018/7/31
-
The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 salesMerck & Co.’s blockbuster cancer drug Keytruda has delivered again in the second quarter, and this time, it has seized the PD-1/L1 crown from Bristol-Myers Squibb’s archrival Opdivo. For the se2018/7/30